Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir

Reuters12-22 20:00

Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals Inc. has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial, which is evaluating the fixed-dose combination regimen of bemnifosbuvir and ruzasvir compared to sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). The C-BEYOND trial is being conducted at approximately 120 clinical sites across the US and Canada. Topline results from this study are expected to be reported in mid-2026. Additionally, the company is advancing the C-FORWARD Phase 3 trial, evaluating the same combination regimen in up to 17 countries outside North America. Enrollment completion for C-FORWARD is anticipated by mid-2026, with topline results expected by year-end 2026. In both studies, bemnifosbuvir and ruzasvir are administered orally once daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis), while the comparator regimen is given for 12 weeks. Results have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605455-en) on December 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593248471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593248471","market":"us","top_or_hot":-1,"title":"Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atea Pharmaceuticals Inc. has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial, which is evaluating the fixed-dose combination regimen of bemnifosbuvir and ruzasvir compared to sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). The C-BEYOND trial is being conducted at approximately 120 clinical sites across the US and Canada. Topline results from this study are expected to be reported in mid-2026. Additionally, the company is advancing the C-FORWARD Phase 3 trial, evaluating the same combination regimen in up to 17 countries outside North America. Enrollment completion for C-FORWARD is anticipated by mid-2026, with topline results expected by year-end 2026. In both studies, bemnifosbuvir and ruzasvir are administered orally once daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis), while the comparator regimen is given for 12 weeks. Results have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605455-en) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atea Pharmaceuticals Inc. has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial, which is evaluating the fixed-dose combination regimen of bemnifosbuvir and ruzasvir compared to sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). The C-BEYOND trial is being conducted at approximately 120 clinical sites across the US and Canada. Topline results from this study are expected to be reported in mid-2026. Additionally, the company is advancing the C-FORWARD Phase 3 trial, evaluating the same combination regimen in up to 17 countries outside North America. Enrollment completion for C-FORWARD is anticipated by mid-2026, with topline results expected by year-end 2026. In both studies, bemnifosbuvir and ruzasvir are administered orally once daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis), while the comparator regimen is given for 12 weeks. Results have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605455-en) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVIR","symbol_name":"Atea Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL25l8NB:1","article_id":"2593248471","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593248471","pubTimestamp":1766404843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atea Pharmaceuticals Inc. has completed enrollment of more than 880 treatment-nave patients in its C-BEYOND Phase 3 trial, which is evaluating the fixed-dose combination regimen of bemnifosbuvir and ruzasvir compared to sofosbuvir and velpatasvir for the treatment of hepatitis C virus . The C-BEYOND trial is being conducted at approximately 120 clinical sites across the US and Canada. Topline results from this study are expected to be reported in mid-2026. Additionally, the company is advancing the C-FORWARD Phase 3 trial, evaluating the same combination regimen in up to 17 countries outside North America. Enrollment completion for C-FORWARD is anticipated by mid-2026, with topline results expected by year-end 2026. In both studies, bemnifosbuvir and ruzasvir are administered orally once daily for 8 weeks  or 12 weeks , while the comparator regimen is given for 12 weeks. Results have not yet been presented.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVIR":"Atea Pharmaceuticals, Inc.","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4585":"ETF&股票定投概念","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4007":"制药","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Atea Pharmaceuticals完成Bemnifosbuvir和Ruzasvir的3期HCV试验入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"AVIR":0.9},"content_text":"Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir\n    \n\n        Atea Pharmaceuticals Inc. has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial, which is evaluating the fixed-dose combination regimen of bemnifosbuvir and ruzasvir compared to sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). The C-BEYOND trial is being conducted at approximately 120 clinical sites across the US and Canada. Topline results from this study are expected to be reported in mid-2026. Additionally, the company is advancing the C-FORWARD Phase 3 trial, evaluating the same combination regimen in up to 17 countries outside North America. Enrollment completion for C-FORWARD is anticipated by mid-2026, with topline results expected by year-end 2026. In both studies, bemnifosbuvir and ruzasvir are administered orally once daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis), while the comparator regimen is given for 12 weeks. Results have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605455-en) on December 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593248471","isCrawlerRequest":true}